Tuesday, March 17, 2026

Misdiagnosed for Years: Ankylosing Spondylitis Cases Rise 1.5 Times Over a Decade

Ankylosing spondylitis is a chronic arthritis affecting young men, causing severe spinal pain and stiffness, requiring early diagnosis.

Over 32,000 Attacks on South Korean Diplomatic Sites from China

Recent data shows that South Korean diplomatic institutions faced the most cyber attacks from China, with over 32,000 attempts reported.

North Korea’s Dark Message: Streetlights Removed on East Sea Highway

It has been confirmed that North Korea...

Tag: immunotherapy

North KoreaKoreaKimMilitarySouth KoreaAIrelationsmarketInternational

How Keytruda is Revolutionizing Cancer Treatment: Expanded Coverage for Stomach Cancer in 2026

Keytruda's insurance coverage expands to stomach cancer, solidifying its status as a leading universal immunotherapy for various cancers.

GCC2005: The Breakthrough CAR-NK Therapy for T-Cell Lymphoma Unveiled at TCLF 2026

GC Cell presents promising CD5-targeting CAR-NK therapy GCC2005 for T-cell lymphoma, showing significant efficacy and safety at TCLF.

Revolutionary Cancer Treatment SJ-650: What Makes It a Game Changer in Oncology?

SillaJen's SJ-650 cancer treatment platform gains recognition with publication in Molecular Therapy, showcasing its innovative approach and efficacy.

Revolutionary mRNA Cancer Treatment Shows 49% Survival Improvement: What You Need to Know

A study shows mRNA-based cancer treatments significantly improve survival rates, marking a breakthrough in precision therapy for melanoma.

Big Pharma Braces for $300 Billion Loss as Blockbuster Drug Patents Expire

Global pharma faces $300B losses from patent expirations, prompting a shift to multi-indication drugs and innovative therapies.

Opdivo Wins EU Approval in Big Step for Early Lung Cancer Treatment

Opdivo gains EU approval for perioperative therapy in NSCLC, enhancing competition with Keytruda and marking a treatment paradigm shift.

A New Era in Precision Oncology—Lunit Unveils 7 AI-Driven Cancer Studies at AACR 2025

Lunit will present AI biomarker studies at AACR 2025, focusing on rare cancers and improving treatment strategies using AI analysis.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.